Golimumab subcutaneous injectable solution is available as a brand-name drug. It’s not available as a generic drug. Brand name: Simponi. Golimumab comes in two injectable forms: a subcutaneous ...

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from ...

The human monoclonal antibody golimumab (Simponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year ...

Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis. SAN FRANCISCO ...

Intravenous golimumab for JIA maintained an acceptable risk-benefit profile in a long-term extension study. The drug’s pharmacokinetics and immunogenicity were consistent up to 244 weeks.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Combination treatment with guselkumab (Tremfya) plus golimumab (Simponi) may hold an advantage over use of either agent ...

Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been approved for the treatment of several autoimmune conditions in adults and children. Whether ...

Golimumab (Simponi), taken with a drug called methotrexate, is recommended as a possible treatment for some adults with severe active rheumatoid arthritis in the same circumstances as other drugs for ...